Form 4: Calidi Biotherapeutics CEO Allan Camaisa Sells 10,000 Shares for Tax Planning

Calidi Biotherapeutics CEO and Chairman Allan Camaisa sold 10,000 shares of common stock at $1.62 per share for tax planning purposes.

Summary

• Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, sold 10,000 shares of common stock on December 17, 2024.
• The sale was executed at a price of $1.62 per share.
• The transaction was conducted for tax planning purposes.
• Following the sale, Mr. Camaisa directly owns 66,712 shares of common stock.
• This total does not include shares issuable upon exercise of options and warrants held by Mr. Camaisa, AJC Capital, LLC, and Jamir Trust, entities he is associated with.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment.

Industry Context

This is a routine SEC Form 4 filing related to insider trading activity. It is common for executives to sell shares for tax planning purposes.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies.
• The sale of 10,000 shares by the CEO is not unusual and does not represent a significant portion of his overall holdings.
• Similar transactions are regularly reported by executives of other biotech companies.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or value.

Key Dates

Keywords

Calidi Biotherapeutics, Allan Camaisa, stock sale, insider trading, SEC Form 4, common stock, tax planning